Solid Biosciences Inc. Revenue
Solid Biosciences Inc. (SLDB) reported Revenue of $8.09 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2023-03-23
- Solid Biosciences Inc. revenues for the quarter ending 2020-12-31 was $0.00.
- Solid Biosciences Inc. revenues for the quarter ending 2020-09-30 was $0.00.
- Solid Biosciences Inc. revenues for the quarter ending 2020-06-30 was $0.00.
- Solid Biosciences Inc. revenues for the quarter ending 2020-03-31 was $0.00.
- Solid Biosciences Inc. revenues for fiscal 2022 was $8.09M, a 40.57% decline from fiscal 2021.
- Solid Biosciences Inc. revenues for fiscal 2021 was $13.62M.
- Solid Biosciences Inc. revenues for fiscal 2020 was $0.00.
- Solid Biosciences Inc. revenues for fiscal 2019 was $0.00.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2022-12-31 | $8.09M 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $13.62M 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $0.00 derived: sum of 2 quarters · filed 2022-03-14 | $0.00 derived: sum of 3 quarters · filed 2022-03-14 | $0.00 10-K · filed 2022-03-14 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-08-06 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-05-07 | $0.00 derived: sum of 3 quarters · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 derived: sum of 3 quarters · filed 2020-11-05 | $0.00 10-K · filed 2022-03-14 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-08-06 | $0.00 derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-05-07 | $0.00 derived: sum of 3 quarters · filed 2020-05-07 | $0.00 derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 10-K · filed 2021-03-15 |
| 2018-09-30 | $0.00 10-K · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 10-Q · filed 2019-11-12 | $0.00 derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $0.00 10-K · filed 2020-03-12 | $0.00 10-Q · filed 2019-08-14 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $0.00 10-K · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-13 | $0.00 derived: sum of 2 quarters · filed 2019-03-13 | $0.00 derived: sum of 3 quarters · filed 2019-03-13 | $0.00 10-K · filed 2020-03-12 |
| 2017-09-30 | $0.00 10-K · filed 2019-03-13 | $0.00 derived: sum of 2 quarters · filed 2019-03-13 | $0.00 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $0.00 10-K · filed 2019-03-13 | $0.00 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $0.00 10-K · filed 2019-03-13 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |